Biosimilars | Access & Reimbursement | US/EU5 | 2018

Payers play a significant role in defining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential reimbursement. Although biosimilars such as Pfizer’s Inflectra are available both in Europe and the United States, the level of their success can vary due to regional differences in the drivers and barriers to biosimilar uptake. As such, it is necessary for biosimilar developers and manufacturers of branded biologics to understand which factors influence payer decisions regarding biosimilars.

Questions answered:

• What are payers’ perspectives on the drivers of and barriers to biosimilar uptake?
• What factors influence which biosimilars are preferred on formularies in the United States?
• How do payers choose between multiple biosimilars of the same brand in the EU?
• What strategies do payers use to manage biosimilars?
• What expectations do payers have for biosimilar discounts?
• How would the availability of biosimilars influence the pricing of emerging agents?
• Will payer strategies for biosimilars differ between therapeutic specialties?

Key markets covered:

• France.
• Germany.
• Italy.
• Spain.
• United Kingdom.
• United States.

Key companies mentioned:

• Amgen.
• Boehringer Ingelheim.
• Celltrion.
• Eli Lilly.
• Hospira.
• Janssen.
• Johnson & Johnson.
• Merck & Co.
• Mundipharma.
• Mylan.
• Novartis.
• Pfizer.
• Roche.
• Samsung Bioepis.
• Sandoz.
• Sanofi.
• Teva.

Key drugs mentioned:

• Aranesp.
• Avastin.
• Basaglar.
• Benepali.
• Binocrit.
• Enbrel.
• Flixabi.
• Genotropin.
• Herceptin.
• Humira.
• Inflectra.
• Lantus.
• Neulasta.
• Neupogen.
• Nivestim.
• Omnitrope.
• Procrit/Epogen.
• Remicade.
• Remsima.
• Rituxan/MabThera.
• Truxima.
• Zarzio/Zarxio.